Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT ID: NCT07335211
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
206 participants
INTERVENTIONAL
2026-01-31
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT04863365
A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
NCT06177678
Intraoperative 5-fluorouracil Augmentation of Trabeculectomy
NCT06745856
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
NCT04448223
Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension
NCT03395535
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HUC3-637
Dorzolamide, Timolol
HUC3-637
Ophthalmic solution instilled directly into the eye (topical ocular administration)
HUC3-637-R
Dorzolamide, Timolol
HUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HUC3-637
Ophthalmic solution instilled directly into the eye (topical ocular administration)
HUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants diagnosed with POAG or OH
* Have fully explained and understood the study and have voluntarily given written informed consent.
Exclusion Criteria
* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huons Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kangbuk Samsung Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUC3-637
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.